» Articles » PMID: 22987963

The Current State of Breast Cancer Classification

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2012 Sep 19
PMID 22987963
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is a highly heterogeneous disease due to its diverse morphological features, the variable clinical outcome and the response to different therapeutic options. It is therefore necessary to devise a clinically meaningful classification of the disease, which has to be scientifically sound, clinically useful and widely reproducible. The established histopathological classification has a limited clinical utility, due to insufficient prognostic and predictive power. More recent classification schemes, based on the immunohistochemical characterization of breast cancer for the assessment of hormone receptor status, HER2 gene over-expression or amplification and the proliferative fraction or on gene expression profiles, correlate much better with the clinical outcome and may be used to inform the choice of the systemic therapy.

Citing Articles

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.

Wawruszak A, Luszczki J, Bartuzi D, Kalafut J, Okon E, Czerwonka A J Enzyme Inhib Med Chem. 2025; 40(1):2458554.

PMID: 39935420 PMC: 11823383. DOI: 10.1080/14756366.2025.2458554.


Correlation Between PIK3R1 Expression and Cell Growth in Human Breast Cancer Cell Line BT-474 and Clinical Outcomes.

Tsai Y, Lai J, Liu C, Hsi C, Hsu C, Huang C World J Oncol. 2025; 16(1):131-141.

PMID: 39850525 PMC: 11750754. DOI: 10.14740/wjon1986.


Lower mRNA Expression and Higher Levels of in HER2-Positive Breast Cancer.

Dix-Peek T, Dickens C, Valcarcel J, Duarte R Biology (Basel). 2024; 13(11).

PMID: 39596875 PMC: 11591975. DOI: 10.3390/biology13110920.


p27 Cell Cycle Inhibitor and Survival in Luminal-Type Breast Cancer: Gene Ontology, Machine Learning, and Drug Screening Analysis.

Park I, Noh Y, Min K, Kim D, Lee J, Son B J Breast Cancer. 2024; 27(5):305-322.

PMID: 39344410 PMC: 11543279. DOI: 10.4048/jbc.2024.0107.


MicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review.

Mohan Lal P, Hamza Siddiqui M, Soulat A, Mohan A, Tanush D, Tirath K Ann Med Surg (Lond). 2024; 86(6):3543-3550.

PMID: 38846828 PMC: 11152842. DOI: 10.1097/MS9.0000000000002075.